Mylene Dorvillius

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 2 EPO patents. Top assignees: Ogd2 Pharma, The University of Nantes. Active years: 2018-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mylene Dorvillius. Retrieved from https://idiyas.com/inventor/mylene-dorvillius

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Nantes, FR (2018 - 2020)
Bouguenais, FR (2022)

Company Filing History:

The University of Nantes

patents

where one patent can have more than one assignee

Years Active: 2018-2022

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11440968 - Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2) (2022-09-13),

2. 10745489 - Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy forcancer (2020-08-18),

3. 10669328 - Human IgG1 derived antibody with pro-apoptotic activity (2020-06-02),

4. 10611848 - Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity (2020-04-07),

5. 10000575 - Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer (2018-06-19),

Title: Mylene Dorvillius: Innovator in Cancer Therapeutics

Introduction

Mylene Dorvillius is a prominent inventor based in Nantes, France. She has made significant contributions to the field of cancer therapeutics, particularly through her innovative work on antibodies targeting specific cancer markers. With a total of 5 patents to her name, Dorvillius is recognized for her groundbreaking research and development in this critical area of medicine.

Latest Patents

Among her latest patents is a humanized antibody against O-acetylated GD2 ganglioside (OAcGD2). This invention discloses an antibody, functional fragment, and derivative that specifically binds to the OAcGD2 ganglioside. The antibody includes a humanized light chain variable region (VL) polypeptide and a humanized heavy chain variable region (VH), both of which have specific amino acid sequences. This antibody is intended for use in diagnostics and therapy. Another notable patent focuses on targeting the O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer. This invention includes an antibody recognizing the O-acetylated-GD2 ganglioside for treating Cancer Stem Cells (CSC) cancer, along with a pharmaceutical composition for treatment and methods for diagnosing CSC cancer.

Career Highlights

Mylene Dorvillius has worked with notable organizations such as Ogd2 Pharma and Université de Nantes. Her work in these institutions has allowed her to advance her research and contribute to the development of innovative cancer treatments.

Collaborations

Some of her coworkers include Jean-Marc Le Doussal and Mickael Terme. Their collaboration has further enriched the research environment and fostered innovation in cancer therapeutics.

Conclusion

Mylene Dorvillius stands out as a leading inventor in the field of cancer research, with her patents paving the way for new diagnostic and therapeutic strategies. Her contributions are vital in the ongoing fight against cancer, showcasing the importance of innovation in medical science.

Profile summary based on public USPTO records.